Summary

CLM-201 was designed to maintain continuous activity of CAR-T cell therapy and to be consistently efficacious against solid tumors by increasing in vivo persistence using a mutation of the CAR-T cell signaling domain structure to regulate the immunosuppressive tumor microenvironment. In addition, its immunosuppressive factors improve the defensive ability of CAR-T targeting solid tumors by inhibiting HGF from creating an immunosuppressive environment by weakening the function of cytotoxic T lymphocyte, or inducing the migration of immunosuppressive neutrophils, etc. in the tumor microenvironment, using the HGF neutralizing antibody, while also inhibiting the activation of cancer cells caused by HGF, facilitating an enhanced dual action attack on the tumor.

Structure and mechanism of action

Technical advantage

- CLM-201 is CellabMED’s next-generation platform to overcome the limitations of CAR-T therapy for solid tumors.

- CLM-201 offers an extended anticancer therapeutic effect.

- CLM-201 protects CAR-T cells and maintains activity by inhibiting the production of immunosuppressive factors by surrounding tumor cells in patients with solid tumors.

- CLM-201 increases the immune cell’s infiltration of solid tumor sites.

Presentation at academic conference

Project	Academic conference	Title of publication	Presentation data
CLM-201	ASGCT 2022	A novel CAR-T cell therapy strategy to inhibit hepetocyte growth factor in solid tumor